Read by QxMD icon Read

Future Oncology

Mark A Baxter, Hilary Glen, Thomas Rj Evans
Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver accounting for approximately 90% of cases. Patients often present at an advanced stage when treatment options are limited. Sorafenib, a multitargeted tyrosine kinase inhibitor, has been the first-line treatment in this setting for almost a decade. Several subsequent targeted therapies have failed to demonstrate significant improvement in survival. The results of the REFLECT study suggest that lenvatinib, a multikinase inhibitor, may have promised as a first-line treatment in patients with advanced HCC...
May 22, 2018: Future Oncology
Maryam Nemati Shafaee, Matthew James Ellis
Fulvestrant is a steroidal selective estrogen receptor degrader that was approved by the US FDA in 2002 for treatment of ER-positive metastatic breast cancer (ER + MBC) post-progression on aromatase inhibitors. In 2016, the label was updated to include endocrine therapy naive ER + MBC. While initially fulvestrant was thought to be equivalent to aromatase inhibitors with monthly dose of 250 mg intramuscular injection, several postmarketing trials challenged this understanding. Subsequently, the recommended dose changed to 500 mg monthly plus loading dose, and this was proven to be superior to anastrozole in efficacy...
May 22, 2018: Future Oncology
Yan Zhang, Jiang Wu, Hong Jing, Gui Huang, Jinlong Dong, Zhanjun Cui
AIM: To explore the expression profile of some DHRS genes in high-grade serous ovarian cancer (SOVC) and to study their prognostic values. PATIENTS & METHODS: A retrospective bioinformatic analysis was performed using data in the Gene Expression Omnibus, the Human Protein Atlas and the Cancer Genome Atlas-Ovarian Cancer. RESULTS: Increased DHRS12 expression was an independent indicator of poor overall survival (hazard ratio [HR]: 1.265; 95% CI: 1...
May 22, 2018: Future Oncology
Sergio Bracarda, Luca Galli, Marco Maruzzo, Giovanni Lo Re, Sebastiano Buti, Adolfo Favaretto, Francesco Di Costanzo, Cosimo Sacco, Marco Merlano, Claudia Mucciarini, Elena Zafarana, Sante Romito, Antonio Maestri, Carmelo G Giorgio, Maria T Ionta, Daniele Turci, Ugo De Giorgi, Giuseppe Procopio, Enrico Cortesi, Diana Giannarelli, Camillo Porta
AIM: We report the outcomes observed with nivolumab in metastatic renal cell carcinoma patients with poor prognostic features enrolled in the Italian expanded access program. PATIENTS & METHODS: Nivolumab was available for patients who relapsed after at least one prior systemic treatment in the advanced or metastatic setting. RESULTS: Of 389 patients, 32 (8%) had brain metastasis, 129 (33%) had liver and 193 (50%) had bone metastasis. These subpopulations achieved a disease control rate of 53, 45 and 47%, respectively...
May 18, 2018: Future Oncology
Hui Huang, Yanze Li, Mingjuan Wu, Jing Luo, Junhui Nie, Baoyu Hou, Qi He, Yan Diao, Lin Qi, Yuanyuan Zhao, Ying Liu, Dan Yang, Lingyun Zhou
AIM: Chondrosarcoma is difficult to treat because of resistance to conventional chemotherapy and radiotherapy. This study evaluated the effects of ethanol in combination with doxorubicin in chondrosarcoma cells. MATERIALS & METHODS: JJ012, was treated with doxorubicin alone or in combination with ethanol. Effects on cellular proliferation, migration, invasion, apoptosis, and the cell cycle were evaluated. RESULTS: Treatment of JJ012 cells with 100 mM ethanol and doxorubicin resulted in reduced cell growth, invasion, and migration...
May 18, 2018: Future Oncology
YokeYong Chen, Mahadir Ahmad
Psychotherapies were offered to alleviate psychological and physical symptoms; however, most psychological interventions were only delivered after cancer treatment. Newly diagnosed cancer patients experienced psychological distress while waiting for treatments. This review paper focused on randomized control trial studies, aimed to investigate the effectiveness of psychological intervention among newly diagnosed cancer patients. Eight randomized control trial papers were found in recent 10 years period through electronic database...
May 16, 2018: Future Oncology
Chengyong Yu, Liyan Hou, Hailing Cui, Liyan Zhang, Xiaodong Tan, Xuejiao Leng, Yingbo Li
AIM: To investigate the potential prognostic value of lactate dehydrogenase-A (LDHA) in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC). PATIENTS & METHODS: Molecular, clinicopathological and survival data in Cancer Genome Atlas-Lung Cancer were obtained for secondary analysis. RESULTS: LDHA expression was significantly upregulated in both LUAD and LUSC compared with normal lung tissues. LUSC tissues had even higher LDHA expression compared with LUAD tissues...
May 14, 2018: Future Oncology
Dong Guo, Jinbao Zhang, Wang Jing, Jiafeng Liu, Hui Zhu, Lei Fu, Minghuan Li, Li Kong, Jinbo Yue, Jinming Yu
AIM: We aimed to investigate the association between systemic immune-inflammation index (SII) and the clinical outcomes in patients with advanced non-small-cell lung cancer. MATERIALS & METHODS: The SII was calculated as platelet (P) × neutrophil (N)/lymphocyte (L), and the data were obtained within 1 week before treatment. Kaplan-Meier analysis and Cox proportional hazard models were used to assess the prognostic value of SII. RESULTS: Kaplan-Meier analyses revealed that the higher SII group was associated with poorer progression-free survival (p < 0...
May 11, 2018: Future Oncology
Peter Reichardt, Marie-Dominique Tabone, Jaume Mora, Bruce Morland, Robin L Jones
Dexrazoxane can prevent anthracycline-associated cardiotoxicity. However, in 2011, its use in children was contraindicated by the EMA over concerns of increased risk of infection, myelosuppression and second primary malignancies, and because its efficacy in children had not then been established. We review here the evidence published since 2011, which confirms that dexrazoxane is an effective cardioprotectant in children and adolescents, is not associated with an increased risk of second primary malignancies or excess early or late mortality and does not impair chemotherapy efficacy...
May 11, 2018: Future Oncology
Omar Abdel-Rahman
AIM: To develop a modified risk stratification scheme for localized prostate cancer incorporating percent of positive cores (PPC). METHODS: Surveillance, Epidemiology and End Results database was accessed for eligible patients. Assessment of the prognostic value of PPC was conducted in a multivariate Cox regression model. A modified risk stratification scheme was proposed. RESULTS: In a multivariate model, higher PPC was associated with worse cancer-specific survival (p < 0...
May 10, 2018: Future Oncology
San-Gang Wu, Qing-Jiang Lin, Feng-Yan Li, Jia-Yuan Sun, Zhen-Yu He, Juan Zhou
AIM: To evaluate the effect of marital status on survival of patients with vulvar cancer. MATERIALS & METHODS: A total of 4001 patients with vulvar cancer were included from the Surveillance, Epidemiology, and End Results database. Statistical analyses were performed using χ2 test, Kaplan-Meier method, Cox regression proportional hazards and a 1:1 propensity score-matching. RESULTS: The 8-year vulvar cancer-related survival in married, divorced, single and widowed patients were 78...
May 10, 2018: Future Oncology
Dan Tan, Feng-Mei Pang, Dan Li, Longbo Zhang, Jun Wu, Zhao-Qian Liu, Xi Li, Han Yan
AIM: To confirm whether the expression level of Fn14 could affect progression or prognosis of glioma patients. METHODS: Glioma cohorts in The Cancer Genome Atlas, Gene Expression Omnibus and Chinese Glioma Genome Atlas databases were comprehensively analyzed. RESULTS: Low-grade patients had lower expression level of Fn14, while patients with higher expression of Fn14 tended to harbor shorter overall survival and disease-free survival. The expression level of Fn14 was downregulated by IDH1/IDH2 mutations while its gene body methylation was upregulated...
May 9, 2018: Future Oncology
Li-Feng Qin, Jin-Mei Qin, Ji-Qiao Zhang, Xiao-Ping Lv, Li-Yi Huang, Jing-Jing Wang
AIM: To determine if CXCL12 (rs1801157) and CXCR4 (rs2228014) polymorphisms are associated with hepatocellular carcinoma (HCC) susceptibility, and detect their expressions in peripheral blood. METHODS: 206 HCC patients, 252 chronic hepatitis B patients, 221 liver cirrhosis patients and 275 healthy volunteers were recruited. Genes CXCL12 and CXCR4 were amplified and genotyped. Their expression in peripheral blood were detected. RESULTS: CXCL12 rs1801157 and CXCR4 rs2228014 polymorphisms were associated with increased susceptibility of HCC, and genotypes GA/AA and CT/TT may be risk factors of HCC (all p < 0...
May 9, 2018: Future Oncology
Dilsa Mizrak Kaya, Bengi Ozturk, Pinar Kubilay, Handan Onur, Gungor Utkan, Filiz Cay Senler, Ali Alkan, Halis Yerlikaya, Elif B Koksoy, Ebru Karci, Ahmet Demirkazik, Hakan Akbulut, Fikri Icli
AIM: There are inconsistent results about the effects of vitamin D level on breast cancer prognosis. We aimed to investigate the effect of vitamin D levels on the prognosis of resectable breast cancer in a patient group with highly different clothing styles. PATIENTS/METHODS: A total of 186 breast cancer patients were enrolled in the study. RESULTS: Vitamin D level was sufficient, insufficient and deficient in 17.2, 52.2 and 30.6% of patients, respectively...
May 9, 2018: Future Oncology
Shi-Hao Dong, Jiong-Qiang Huang, Jing-Song Chen
Accumulated evidence has shown that colonoscopy may not be a perfect tool in screening and reducing the incidence of the colorectal cancer (CRC), because interval CRC (I-CRC), a specific subgroup of CRCs, has been challenging the traditional detection technology in recent years. I-CRC is accounting for an increasing proportion in CRCs. However, the effective procedures to prevent and supervise I-CRC need to be explored. In this review, we summarized the incidence, causes, risk factors, characteristics and management of I-CRC...
May 9, 2018: Future Oncology
Shweta Lawania, Siddharth Sharma, Navneet Singh, Digamber Behera
AIM: To evaluate the association of three XPF polymorphic variants (673 C>T, 11985 A>G, G415A) with lung cancer, overall survival and clinical response in North Indians. METHODS: Genotyping was performed using PCR-restriction fragment length polymorphism. RESULTS: A total of 673 C>T polymorphism was associated with 1.5-fold increased lung cancer risk for heterozygous genotype (CT; p = 0.03). Adenocarcinoma patients with 673 C>T polymorphism carrying heterozygous genotype (CT) had a lower hazard ratio (p = 0...
May 9, 2018: Future Oncology
Enrico Franceschi, Giuseppe Lamberti, Michela Visani, Alexandro Paccapelo, Antonella Mura, Giovanni Tallini, Annalisa Pession, Dario De Biase, Santino Minichillo, Alicia Tosoni, Monica Di Battista, Alessio Cubeddu, Stefania Bartolini, Alba A Brandes
AIM: To identify patients with recurrent glioblastoma after temozolomide (TMZ) concurrent with and adjuvant to radiotherapy who could benefit from TMZ rechallenge at the time of disease progression. METHODS: We retrospectively evaluated 106 glioblastoma patients who had nonprogressive disease at first magnetic resonance imaging after completion of TMZ concurrent with and adjuvant to radiotherapy, a treatment-free interval (TFI) of at least 8 weeks and received TMZ rechallenge or a nitrosourea at the time of progression...
May 9, 2018: Future Oncology
Joseph J Sacco, Helen Kalirai, Jenna Kenyani, Carlos R Figueiredo, Judy M Coulson, Sarah E Coupland
No abstract text is available yet for this article.
May 9, 2018: Future Oncology
Mark McGregor, Timothy J Price
The humanized monoclonal antibody panitumumab, targeted against EGFR, plays an important role in patients with metastatic colorectal cancer. This article reviews the body of evidence for panitumumab which demonstrates significant benefits across multiple lines of therapy in those without an extended RAS mutation. The use of panitumumab with RAS mutations is not beneficial and possibly harmful. Panitumumab is well tolerated with manageable toxicities. The role of panitumumab continues to evolve as understanding of sequencing of therapies grows...
May 8, 2018: Future Oncology
Janette Beech, Theodora Germetaki, Mary Judge, Nina Paton, Joanne Collins, Abigail Garbutt, Michael Braun, Jill Fenwick, Mark P Saunders
Cutaneous toxicities associated with EGFR inhibitors (EGFRIs) have a significant impact on patient treatment continuation, quality of life and healthcare resource utilization. This paper reviews the current prophylaxis and management of EGFRI-induced cutaneous toxicities in patients with colorectal cancer, and combines these findings with the authors' clinical expertise to define a novel algorithm for healthcare professionals managing patients receiving EGFRIs. This tool includes a grading system based on the location, severity and psychological impact, and provides a standard prescription pack, advice on prophylaxis/self-management of cutaneous symptoms for patients initiating EGFRIs, and essential guidance on subsequent review and treatment escalation...
May 4, 2018: Future Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"